PF-Atlas › Clinical Trials › NCT00162760
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
Thalidomide · Phase 2
Registry ID
NCT00162760
Phase
Phase 2
Status
Completed
Drug / intervention
Thalidomide
Sponsor
Johns Hopkins University
Start
2003-10
Enrollment
19
Locations
1
About this trial
The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide administered daily for one year in patients with idiopathic pulmonary fibrosis (IPF) who have failed or are not candidates for treatment with corticosteroids and/or cytotoxic drugs. The study population will consist of patients with biopsy-proven moderate to severe IPF who have failed or are not candidates for standard therapy with corticosteroids and/or cytotoxic drugs.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00162760 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.